# US 2018/0338847 A1 · Optimized stent jacket having single fiber mesh

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0338847 A1
- Document ID: US20180338847A1
- Status: Published application
- Kind: A1
- Application number: 16/052,301
- Filed: 2018-08-01
- Published: 2018-11-29
- Earliest claimed: 2006-11-22
- Assignees: Inspiremd, Ltd.
- Applicants: Inspiremd, Ltd.
- Inventors: Asher HOLZER; Eli BAR; Ofir PAZ
- Web page: https://patentgrep.com/patent/US20180338847A1

## CPC

- A61F 2/90: characterised by a net-like or mesh-like structure
- A61F 2/0063: {Implantable repair or support meshes, e.g. hernia meshes}
- A61F 2/07: Stent-grafts
- A61F 2/82: Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07)
- A61L 31/022: {Metals or alloys}
- A61L 31/048: {obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence)}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/10: Macromolecular materials
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- C08G 63/00: Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule (polyester-amides C08G69/44; polyester-imides C08G73/16)
- C08G 63/06: derived from hydroxycarboxylic acids
- C08G 63/08: Lactones or lactides
- C08G 63/40: Polyesters derived from ester-forming derivatives of polycarboxylic acids or of polyhydroxy compounds, other than from esters thereof
- C08G 73/02: Polyamines
- C08G 79/04: Phosphorus linked to oxygen or to oxygen and carbon
- A61F 2/89: the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
- A61F 2002/0086: {for preferentially controlling or promoting the growth of specific types of cells or tissues}
- A61F 2002/075: {the stent being loosely attached to the graft material, e.g. by stitching}
- A61F 2002/823: {Stents, different from stent-grafts, adapted to cover an aneurysm}
- A61F 2210/0004: bioabsorbable
- A61F 2210/0076: multilayered, e.g. laminated structures
- A61F 2240/001: Designing or manufacturing processes
- A61F 2250/0023: differing in porosity
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61L 2300/604: Biodegradation
- A61L 2300/606: Coatings
- A61L 2420/02: Methods for coating medical devices
- Y10T 29/49964: At least one part nonmetallic
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

An intravascular device configured to treat an aneurysm that includes a support structure including metal struts configured to be positioned in a body lumen and defining a central fluid passage that extends axially along the support structure, and a knitted mesh cover disposed over an exterior thereof and across a radial arc and along a length of the support structure sufficient to exceed an opening of an aneurysm to be treated, and the cover includes a polymer fiber having a diameter of at least 40 nanometers to 30 microns and apertures therethrough, the apertures being sized to prevent blood from passing through the device to prevent further expansion of the aneurysm. Devices including apertures that are at least 20 microns and sized to minimize or prevent an aneurysm-filling material from exiting the aneurysm through the knitted mesh cover and support structure, and methods of stenting, are also encompassed.

## Claims

### Claim 1

A method of stenting, which comprises:
implanting a stent assembly in a vessel of a subject, the stent assembly, including:
i. a knitted stent jacket, comprising an expansible mesh structure formed from a single fiber having a diameter from about 7 micrometers to about 40 micrometers; and
ii. an expansible stent, operatively associated with the stent jacket,
wherein the expansible mesh structure comprises a retracted state and a deployed state, wherein the expansible mesh structure defines apertures having a minimum center dimension greater than 160 micrometers in the deployed state, and wherein the expansible mesh structure has a thickness of greater than 12.5 micrometers to less than 100 micrometers.

### Claim 2

A method of stenting, which comprises:
implanting a stent assembly in a vessel of a subject, the stent assembly, including:
i. a stent jacket, comprising an expansible mesh structure, knitted from a single fiber having a diameter from about 7 micrometers to about 40 micrometers; and
ii. an expansible stent, operatively associated with the stent jacket, wherein the expansible mesh structure comprises a retracted state and a deployed state, wherein the expansible mesh structure defines apertures having a minimum center dimension greater than 100 micrometers and below 300 micrometers when the expansible mesh structure is in the deployed state, and wherein the expansible mesh structure has a thickness of greater than 12.5 micrometers to less than 100 micrometers.

### Claim 3 (depends on 2)

The method of claim 2, wherein the fiber diameter is from about 10 to about 20 micrometers.

### Claim 4 (depends on 2)

The method of claim 2, wherein the expansible mesh structure has a thickness of less than 30 micrometers and the fiber diameter is less than the thickness of the expansible mesh structure.

### Claim 5 (depends on 2)

The method of claim 2, wherein the fiber of the expansible mesh structure directly contacts a second fiber of the expansible mesh structure at each of a plurality of fiber junctions.

### Claim 6 (depends on 2)

The method of claim 2, wherein the expansible mesh structure defines apertures having a minimum center dimension of greater than about 160 micrometers.

### Claim 7 (depends on 6)

The method of claim 6, wherein an amount of porous structure surface area of the stent jacket dedicated to structure is less than about 12%.

### Claim 8 (depends on 2)

The method of claim 2, wherein the fiber is formed of a biostable polymer or a natural polymer.

### Claim 9 (depends on 2)

The method of claim 2, wherein the fiber of the expansible mesh structure directly contacts a second portion of the fiber of the expansible mesh structure at each of a plurality of fiber junctions.

### Claim 10 (depends on 2)

The method of claim 2, wherein the stent is adapted to treat an aneurism.

### Claim 11 (depends on 2)

The method of claim 2, wherein the stent is adapted to support a blood vessel.

### Claim 12 (depends on 2)

The method of claim 2, wherein the stent is adapted to dilate a body lumen.

### Claim 13

A stent assembly, which comprises:
a. a knitted stent jacket, comprising an expansible mesh structure formed from a single fiber having a diameter from about 7 micrometers to about 40 micrometers; and
b. an expansible stent, operatively associated with the stent jacket,
wherein the expansible mesh structure comprises a retracted state and a deployed state, and the expansible mesh structure defines apertures having a minimum center dimension greater than 100 micrometers and below 300 micrometers when the expansible mesh structure is in the deployed state, and
wherein the expansible mesh structure has a thickness of greater than 12.5 micrometers to less than 100 micrometers.

### Claim 14 (depends on 13)

The stent assembly according to claim 13, wherein the fiber diameter is from about 11 micrometers to about 20 micrometers.

### Claim 15 (depends on 13)

The stent assembly according to claim 13, wherein the fiber diameter is from about 15 micrometers to about 20 micrometers.

### Claim 16 (depends on 13)

The stent assembly according to claim 13, wherein the mesh is formed as a single knit.

### Claim 17 (depends on 13)

The stent assembly according to claim 13, wherein in the deployed state, the expansible mesh structure defines apertures, having a minimum center dimension, which is greater than about 160 micrometers, thus minimizing occurrences of a single endothelial cell adhering to more than one fiber, across one of the apertures, and reducing a chance of endothelial cells breaking free as a result of natural stent pulsation with blood flow.

### Claim 18 (depends on 13)

The stent assembly according to claim 13, wherein the minimum center dimension is greater than about 180 micrometers.

### Claim 19 (depends on 13)

The stent assembly according to claim 13, wherein the stent jacket comprises a coverage area of between about 9% and about 12% of the surface area of the stent.

### Claim 20 (depends on 13)

The stent assembly according to claim 13, wherein the fiber is formed of a material that encourages stable adherence of endothelial cells thereto.

### Claim 21 (depends on 20)

The stent assembly according to claim 20, wherein the material is selected from the group consisting of: stainless steel, nitinol, titanium, gold, a biostable polymer, and a natural polymer.

### Claim 22 (depends on 13)

The stent assembly according to claim 13, wherein the fiber of the expansible mesh structure directly contacts a second portion of the fiber of the expansible mesh structure at each of a plurality of fiber junctions.

### Claim 23 (depends on 13)

The stent assembly according to claim 13, wherein the fiber comprises a biostable polymer or a natural polymer.

### Claim 24 (depends on 13)

The stent assembly of claim 13, wherein the expansible mesh structure extends past at least one end of the expansible stent.

### Claim 25 (depends on 24)

The stent assembly of claim 24, wherein the expansible mesh structure extends past both ends of the expansible stent.

### Claim 26 (depends on 13)

The stent assembly of claim 13, wherein the fiber comprises polyethylene terephthalate (PET).

### Claim 27 (depends on 13)

The stent assembly of claim 13, the stent jacket, the expansible stent, or both, are adapted to elute one or more pharmaceutical agents for treatment of a body lumen.

### Claim 28 (depends on 27)

The stent assembly of claim 27, wherein the one or more pharmaceutical agents is associated with the expansible mesh structure by: being deposited in the apertures of the expansible mesh structure, mixed into the fiber of the expansible mesh structure, applied topically to the expansible mesh structure, applied by dipping the expansible mesh structure therein, being encapsulated on the expansible mesh structure, grafted onto the expansible mesh structure by plasma treatment, etched into the expansible mesh structure, or migrated into the expansible mesh structure, or a combination thereof.

### Claim 29 (depends on 13)

The stent assembly of claim 13, which further comprises a polymer coating associated with the expansible mesh structure, wherein the polymer coating contains one or more pharmaceutical agents.

### Claim 30 (depends on 29)

The stent assembly of claim 29, wherein the one or more pharmaceutical agents comprises a first pharmaceutical agent to be eluted, and a second pharmaceutical agent to be eluted thereafter.
